What does this research mean for the field?

Despite numerous patents for drugs targeting mPGES-1 to reduce PGE2 in inflammation, no selective inhibitors have been identified and none have reached clinical trials. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

February 26, 2013Open Access

Targeting Inflammation: Multiple Innovative Ways to Reduce Prostaglandin E 2

Structured PICO

I

Intervention

Drugs targeting mPGES-1 and other modulators of free extracellular PGE2 concentration

Despite numerous patents, no selective mPGES-1 inhibitors have reached clinical trials for inflammation-driven diseases.

Abstract

The PGE2 pathway is important in inflammation-driven diseases and specific targeting of the inducible mPGES-1 is warranted due to the cardiovascular problems associated with the long-term use of COX-2 inhibitors. This review focuses on patents issued on methods of measuring mPGES-1 activity, on drugs targeting mPGES-1 and on other modulators of free extracellular PGE2 concentration. Perspectives and conclusions regarding the status of these drugs are also presented. Importantly, no selective inhibitors targeting mPGES-1 have been identified and, despite the high number of published patents, none of these drugs have yet made it to clinical trials.

Targeting Inflammation: Multiple Innovative Ways to Reduce Prostaglandin E 2

Structured PICO

Abstract

Cite This Study

Also Consider

Also Consider